Search results
About Me. Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and ...
- 1470 Madison Avenue, 3rd Floor, New York, 10029, NY
- shanez.stanisclaus@mssm.edu
- (212) 241-6756
Joshua Brody (I) Actor. IMDbPro Starmeter See rank. Joshua Brody was born in Summit, New Jersey to parents Alan and Miriam Brody. Living in Short Hills, New Jersey, Joshua moved to London, England in 1993 and has been there ever since. He currently attends The American School in London and will be a senior in the 2002-2003 school year.
- Actor
- April 20, 1985
- Joshua Brody
Health Tip: Exercising After Breast Cancer. Dr. Joshua Brody is a Oncologist in New York, NY. Find Dr. Brody's phone number, address, insurance information, hospital affiliations and more.
- (21)
- (332) 239-6252
- New York, NY
Graduate School of Biomedical Sciences. Icahn Genomics Institute. Icahn School of Medicine at Mount Sinai. Marc and Jennifer Lipschultz Precision Immunology Institute. Medicine. Medicine - Hematology and Medical Oncology. The Tisch Cancer Institute. Email joshua.brody @ mssm. edu. h-index.
Joshua Brody, MD, is Associated Professor and the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute.
2013. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab …. KJ Harrington, J Brody, M Ingham, J Strauss, S Cemerski, M Wang, A Tse, ... Annals of Oncology 29, viii712.
Jul 11, 2018 · Joshua Brody, MD, assistant professor of medicine, hematology and medical oncology, director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, discusses recent advances in immunotherapy, anti-body drug conjugates, and targeted and combination therapies for Hodgkin lymphoma patients. Dr.
